Bromazolam cas 71368-80-4

Description Bromazolam is classified as a novel benzodiazepine which was first synthesised in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified by the EMCDDA in Sweden in 2016. It is the bromo instead of chloro analogue of alprazolam, and has similar sedative and anxiolytic effects. Bromazolam is structurally similar to traditional benzodiazepines, including alprazolam (replacing the chlorine with a bromine) and bromazepam (addition of triazole ring). Alprazolam and bromazepam are Schedule IV substances in the United States; bromazolam is not explicitly scheduled.
Uses 8-Bromo-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine is used to study the antianxiety activity, antidepressant and psychotropics for central nervous system.
Application Bromazolam(8bromo) is a synthetic cannabinoid that has been used as an alternative to marijuana. It has been shown to induce psychosis in animals and humans and is associated with high rates of depression. 8bromo was found to be effective against cancer cells in vitro and in vivo, but not against bacteria or fungi. In humans, 8bromo increased the levels of liver enzymes. This agent has also been shown to have antiinflammatory properties that are mediated by prostaglandin synthesis inhibition.
twitter: @Michelle7077

Email:*